and having to adjust the dose of the drug if not. "The Appraisal Committee felt that dabigatran represents a potential benefit for many people who have had a DVT or PE, particularly those who have ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa ... particularly when outpatient dosing is required after early discharge.

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, tolerability, dosage and administration, and place in therapy of dabigatran etexilate are reviewed. Summary. Dabigatran is a ...